A 54-year-old woman with peripheral T cell lymphoma in second complete remission (CR) received an autologous peripheral blood stem cell transplant (PBSCT). Antibiotic-resistant bloody diarrhea, and fever developed 110 days after transplant. Blood and stool cultures were negative. Skin rash was not observed. Barium enema and colonoscopy showed typical features of pancolonic-type ulcerative colitis (UC). Endoscopic biopsies confirmed the diagnosis of UC. Mesalazine and immunosuppressive therapy improved symptoms dramatically. We detected serum antibodies against synthetic tropomyosin (TM) peptide when UC was diagnosed. We postulate that autoimmunity including autoreactive anti-TM antibodies may be involved in the pathogenesis of UC after autologous PBSCT in this patient. Bone Marrow Transplantation (2001) 28, 619-621.
1 autoimmune neutropenia, 2 and autoimmune thyroiditis 3 may develop following autologous, as well as allogeneic, hematopoietic stem cell transplantation (HSCT). These may develop via an immune system imbalance due to insufficient numbers or inadequate function of suppressor T cells in the early post-graft period, delayed recovery of regulatory T cells, or subsequent reactivation of autoreactive T cells. 4 Autoimmune phenomena have similarly been implicated in the pathogenesis of ulcerative colitis (UC). To date, two cases of UC following allogeneic HSCT have been reported, 5, 6 one of which is thought to be transmission of inflammatory bowel disease from donor to recipient. 6 However, no cases of UC following autologous HSCT have been reported. We describe a case of UC following autologous peripheral blood stem cell transplantation (PBSCT) for non-Hodgkin's lymphoma.
Case report
A 54-year-old Japanese woman was diagnosed with advanced peripheral T cell lymphoma (stage IIIA) in November 1995, and a complete remission (CR) was achieved with six cycles of E-CHOP (etoposide, cyclophosphamide, doxorubicin, vincristine, and prednisolone). There was no clinical history of UC or other autoimmune disease before the first hospitalization. In September 1996, the patient was readmitted because of relapse in a right axillary lymph node.
The clinical course is shown in Figure 1 . A second CR was achieved following salvage therapy consisting of carboplatin, pirarubicin, etoposide, cyclophosphamide, mitoxantrone, bleomycin, and prednisolone. In November 1996, PBSC were mobilized with cytosine arabinoside (Ara-C), 8 g/m 2 in four divided doses for 2 days, followed by granulocyte colony-stimulating factor (G-CSF) 5 g/kg/day; 6.1 ϫ 10 6 CD34-positive cells/kg were collected. Conditioning consisted of cyclophosphamide 60 mg/kg i.v. on days −7, and −6, etoposide 500 mg/m 2 i.v. on days −6, −5, and −4, and ranimustine 250 mg/m 2 i.v. on days −3, and −2. Unpurged PBSC were reinfused on day 0. Recombinant human G-CSF was given by subcutaneous injection (5 g/kg/day) from day 1 until the granulocyte count exceeded 5 ϫ 10 9 /l. Granulocytes exceeded 0.5 ϫ 10 9 /l on day 10. The last platelet transfusion was on day 11, and trilineage hematopoietic recovery was achieved within 3 weeks of PBSCT. Regimen-related toxicities were minimal and the patient had an uneventful course without recurrence of lymphoma.
On day +110, she complained of high fever and watery diarrhea containing blood. Antibiotics, bowel rest, and total parenteral nutrition did not improve the symptoms, which were dominated by 15 to 20 watery stools a day. Autologous graft-versus-host disease (GVHD)-like skin rash was not observed throughout the post-transplant period. No pathogenic organisms were cultured from either blood or stool; a latex detection test for Clostridium difficile was negative. Cytomegalovirus (CMV) pp65 antigenemia test was negative. A barium enema demonstrated typical features of ulcerative colitis of the pancolonic type, including spiculation, lead-pipe appearance, and loss of the haustral pattern. Colonoscopy confirmed hemorrhage, multiple ulcers, loss of the mucosal vascular pattern, highly increased friability and mucosal edema extending from the rectum to the ascending colon. Biopsies of the colonic mucosa showed severe neutrophilic infiltration with crypt abscesses consistent with UC ( Figure 2) .
Intranuclear inclusion bodies of CMV were not found, Figure 2 Histologic appearance of colon biopsy specimen shows severe neutrophilic infiltration with crypt abscess formation (arrows). Hematoxylin and eosin; original magnification × 50.
and immunohistochemical stains with monoclonal antibodies against CMV antigens were negative. Cultures of colonic specimens were negative for CMV, and CMV DNA was not detected in biopsy specimens by polymerase chain reaction (PCR). There were no microscopic findings suggestive of GVHD, including apoptotic bodies and intraepithelial lymphocytic infiltration. From these observations, we made the diagnosis of active UC, pancolonic type. Treatment was initiated with oral steroid therapy (1 mg/kg/day prednisolone, ie 45 mg) and oral mesalazine (1500 mg/day). Symptoms improved initially but relapsed with a decrease in steroid dose 2 months later. Cyclosporine (CsA) (325 mg/day) was started, in addition to increasing oral prednisolone to 45 mg/day. After these treatments, the clinical symptoms and colonoscopic findings of UC disappeared gradually. At 3 years follow-up, the patient remains well off steroids, CsA, and mesalazine without recurrence of UC or lymphoma. Peripheral lymphocyte subsets by flow cytometry on day -14 (pre-transplantation) showed CD4 + and CD8 + T cells to be 42.5% and 19.5%, respectively. On day +7, the percentages of CD4 + and CD8 + T cells were 39.9% and 20.4.%, and when UC developed on day +128, the percentages of CD4 + and CD8 + T cells were 26.5% and 41.4.%, respectively.
We studied anti-tropomyosin (TM) antibody which may be detected in UC sera by a specific peptide-based enzymelinked immunosorbent assay (ELISA) as previously reported. 7 Antibody titers were represented by optical density (OD) values at 405 nm. The normal range was defined as 0.04 to 0.6, OD values from 40 healthy volunteers (mean Ϯ2 s.d.; 0.32 Ϯ 0.28). As shown in Figure 1 , on day −14, the anti-TM titer in this patient's serum was negative (0.41) and remained so (0.52) on day +14 after PBSCT. On day +128, when UC developed, the anti-TM titer was positive (0.64), then decreased (0.30) with remission on day +345.
Discussion
Autoimmune disease may follow HSCT. Autoimmune cytopenias, thyroid diseases, and myasthenia gravis are the most common autoimmune phenomena that develop after HSCT. 8 Formation of autoantibodies may result from a transient immune system imbalance during re-establishment of the normal immune and hematopoietic systems. Ishikawa et al 3 reported a patient who developed autoimmune thyroiditis following autologous PBSCT; generation of autoreactive antibodies may have been due to delayed recovery of regulatory T cells and subsequent reactivation of autoreactive T cells. Lambertenghi et al 9 reported a patient with myelodysplastic syndrome who underwent autologous BMT and subsequently developed multiple, sequential, and clinically relevant autoantibodies despite a hematologic CR. Some authors have postulated that there may be a deficiency in antigen-specific suppressor activity, related to delayed engraftment, involving certain CD8
+ clones. Most cases of autoimmune disease following HSCT have been associated with cytopenia, such as thrombocytopenia and neutropenia. Relevant to UC after HSCT, Spiers 5 reported a case of UC which developed 3 years after allogeneic BMT for acute lymphocytic leukemia. There is another report of UC which may have been transmitted from donor to recipient after allogeneic BMT. 6 However, no cases of UC have previously been reported following autologous HSCT.
Diarrhea with fever can be caused by intestinal infections or chemotherapy-related toxicity in HSCT recipients. In the present case, both infection and toxicity of anticancer drugs were excluded, and both endoscopic and pathologic findings of the colon confirmed the diagnosis of UC after autologous PBSCT. Moreover, treatments for UC (mesalazine and immunosuppressive therapy) improved the symptoms dramatically. Detection of anti-TM antibody, thought to be one of the diagnostic autoantibodies for UC, indicated a correlation between autologous PBSCT and generation of autoantibodies.
Several autoantibodies have been reported in UC. 10, 11 TM has been identified as a putative auto-antigen of UC. Das et al 10 detected antibody reacting against porcine TM in UC sera. Recently, Sakamaki et al 7 reported that anti-TM antibody may be involved in the pathogenesis of UC. Anti-TM antibody in our patient became positive when UC became symptomatic, but disappeared with remission although we could not study other autoantibodies associated with UC. These results indicate that TM antibodies may play an important role in the etiology of UC after PBSCT at least in the present case. This effect may be related either to a specific decrease in helper T cell activity or enhancement of suppressor T cell activity.
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UC is characterized by altered mucosal and systemic immune responses. In the present case, the pattern of peripheral lymphocyte subset reconstitution after PBSCT revealed alterations in peripheral CD4 and CD8 percentages, changing from 39.9% to 26.5% and from 20.4% to 41.4%, respectively, when UC developed; however, a decreased CD4/CD8 ratio can occur in transplant patients who do not have autoimmune disease. Kramer et al 12 reported that patients with UC had either specific deficiencies in helper T cell activity or enhancement of suppressor T cell activity in peripheral blood. Although we could not examine the lymphocyte subsets in colonic mucosa, and the difference in immune alteration between the cases who develop autoimmune disease and the cases who do not develop remain unclear, immune system imbalance after transplantation seems a possible cause of UC following autologous HSCT.
